Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Journal

Publication Venue For

  • Associations between multiple forms of discrimination and tobacco use among people living with HIV: The mediating role of avoidance coping.  78:9-15. 2019
  • Brief report: The association of chronic pain and long-term opioid therapy with HIV treatment outcomes.  79:77-82. 2018
  • Assessing the association between changing NRTIs when initiating second-line ART and treatment outcomes.  77:413-416. 2018
  • Stigma reduction among African American women With HIV: UNITY health study.  78:269-275. 2018
  • HIV Care Initiation Delay among Rural Residents in the Southeastern United States, 1996 to 2012.  76:171-176. 2017
  • Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared with the General Population.  75:568-576. 2017
  • Brief Report: IL-1β Levels Are Associated with Chronic Multisite Pain in People Living with HIV.  75:e99-e103. 2017
  • Budgetary impact of compliance with sti screening guidelines in persons living with HIV.  74:303-308. 2017
  • Higher cystatin c levels are associated with neurocognitive impairment in older HIV+ adults.  74:243-249. 2017
  • Elevated markers of vascular remodeling and arterial stiffness are associated with neurocognitive function in older HIV+ adults on suppressive antiretroviral therapy.  74:134-141. 2017
  • An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM.  74:21-29. 2017
  • Association between internalized HIV-related stigma and HIV care visit adherence.  76:482-487. 2017
  • Brief Report: Factors Associated with the Selection of Initial Antiretroviral Therapy from 2009 to 2012.  74:60-64. 2017
  • Brief Report: Interpersonal and Intrapersonal Factors as Parallel Independent Mediators in the Association between Internalized HIV Stigma and ART Adherence.  74:e18-e22. 2017
  • Brief Report: The Right People, Right Places, and Right Practices: Disparities in PrEP Access among African American Men, Women, and MSM in the Deep South.  74:56-59. 2017
  • The relationship between efavirenz as initial antiretroviral therapy and suicidal thoughts among HIV-infected adults in routine care.  76:402-408. 2017
  • First-in-human trial of MIV-150 and zinc acetate coformulated in a carrageenan gel: Safety, pharmacokinetics, acceptability, adherence, and pharmacodynamics.  73:489-496. 2016
  • Heavy alcohol use is associated with worse retention in HIV care.  73:419-425. 2016
  • Improving depression among HIV-infected adults: Transporting the effect of a Depression Treatment Intervention to Routine Care.  73:482-488. 2016
  • Higher time-updated body mass index: Association with improved CD4+ cell recovery on HIV treatment.  73:197-204. 2016
  • Single viral load measurements overestimate stable viral suppression among HIV patients in care: Clinical and public health implications.  73:205-212. 2016
  • Poorly controlled HIV infection: An independent risk factor for liver fibrosis.  72:437-443. 2016
  • An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African Women.  72:333-343. 2016
  • Mechanisms for the negative effects of internalized HIV-related stigma on antiretroviral therapy adherence in women: The mediating roles of social isolation and depression.  72:198-205. 2016
  • When to monitor CD4 cell count and HIV RNA to reduce mortality and aids-defining illness in virologically suppressed hiv-positive persons on antiretroviral therapy in high-income countries: A prospective observational study.  72:214-221. 2016
  • Enhanced allogeneic cellular responses to mismatched HLA-B antigens results in more efficient killing of HIV infected cells.  71:493-497. 2016
  • Bone mineral density changes among young, healthy African women receiving oral tenofovir for HIV preexposure prophylaxis.  71:287-294. 2016
  • HIV-infected ugandan women on antiretroviral therapy maintain HIV-1 RNA suppression across periconception, pregnancy, and postpartum periods.  71:399-406. 2016
  • Oral lopinavir use and human papillomavirus infection in HIV-positive women.  70:e63-e66. 2015
  • An Algorithm Approach to Determining Smoking Cessation Treatment for Persons Living With HIV/AIDS: Results of a Pilot Trial.  69:291-298. 2015
  • Clinic-wide intervention lowers financial risk and improves revenue to HIV clinics through fewer missed primary care visits.  68:472-476. 2015
  • Effect of hormonal contraception on the function of plasmacytoid dendritic cells and distribution of immune cell populations in the female reproductive tract.  68:511-518. 2015
  • Effects of Antenatal Care and HIV Treatment Integration on Elements of the PMTCT Cascade: Results from the SHAIP Cluster-Randomized Controlled Trial in Kenya.  69:e172-e181. 2015
  • Enhanced recognition of HIV-1 cryptic epitopes restricted by HLA Class I alleles associated with a favorable clinical outcome.  70:1-8. 2015
  • Estimating the cost of increasing retention in care for HIV-infected patients: Results of the CDC/HRSA retention in care trial.  68:345-350. 2015
  • Immune reconstitution but persistent activation after 48 weeks of antiretroviral therapy in youth with pre-therapy CD4 >350 in ATN 061.  69:52-60. 2015
  • Impact of age on retention in care and viral suppression.  68:413-419. 2015
  • Implementation and Operational Research: Effect of Integration of HIV Care and Treatment into Antenatal Care Clinics on Mother-to-Child HIV Transmission and Maternal Outcomes in Nyanza, Kenya: Results from the SHAIP Cluster Randomized Controlled Trial.  69:e164-e171. 2015
  • Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration.  69:348-354. 2015
  • Phase 1 safety, pharmacokinetics, and pharmacodynamics of dapivirine and maraviroc vaginal rings: A double-blind randomized trial.  70:242-249. 2015
  • Rates and correlates of antiretroviral therapy use and virologic suppression among perinatally and behaviorally HIV-infected youth linked to care in the United States.  68:169-177. 2015
  • Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: A randomized phase 2 study.  69:439-445. 2015
  • Depression during pregnancy and the postpartum among HIV-infected women on antiretroviral therapy in Uganda.  67:S179-S187. 2014
  • Eliminating preventable HIV-related maternal mortality in Sub-Saharan Africa: What do we need to know?.  67:S250-S258. 2014
  • HIV-positive status disclosure and use of essential PMTCT and maternal health services in rural Kenya.  67:S235-S242. 2014
  • Lost opportunities to reduce periconception HIV transmission: Safer conception counseling by South African providers addresses perinatal but not sexual HIV transmission.  67:S210-S217. 2014
  • High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.  67:91-97. 2014
  • Raltegravir pharmacokinetics in neonates following maternal dosing 2014
  • Genital tract HIV RNA levels and their associations with human papillomavirus infection and risk of cervical precancer.  66:316-323. 2014
  • Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1.  66:65-73. 2014
  • Factors associated with delayed hepatitis b viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort.  66:96-101. 2014
  • Antiretroviral therapy restores age-dependent loss of resting memory B cells in young HIV-Infected zambian children.  65:505-509. 2014
  • Genital tract HIV RNA levels and their associations with human papillomavirus infection and risk of cervical pre-cancer 2014
  • Pregnancy Intentions Among Women Living With HIV in the United States.  65:306-311. 2014
  • Characterization of T-Cell responses to cryptic epitopes in recipients of a noncodon-optimized HIV-1 Vaccine.  65:142-150. 2014
  • The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment.  65:190-197. 2014
  • Addressing standards of care in resource-limited settings.  65. 2014
  • Changes in cellular immune activation and memory T-cell subsets in HIV-infected Zambian children receiving HAART.  67:455-462. 2014
  • Managing multiple funding streams and agendas to achieve local and global health and research objectives: Lessons from the field.  65. 2014
  • Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care.  64:254-260. 2013
  • Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.  64:167-173. 2013
  • Global maternal and child health goals will not be achieved without addressing HIV-related stigma.  64. 2013
  • High levels of antiretroviral use and viral suppression among persons in HIV care in the United States, 2010.  63:299-306. 2013
  • Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the united states, 2000-2010.  63:216-220. 2013
  • Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: Final 5-year results from STARTMRK.  63:77-85. 2013
  • Erratum: Pain, mood, and substance abuse in HIV: Implications for clinic visit utilization, antiretroviral therapy adherence, and virologic failure (Journal of Acquired Immune Deficiency Syndromes (2012) 61 (164-170).  63. 2013
  • Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation.  62:505-508. 2013
  • Invasive cervical cancer risk among HIV-infected women: A North American multicohort collaboration prospective study.  62:405-413. 2013
  • The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men.  62:447-456. 2013
  • Retention among North American HIV-infected persons in clinical care, 2000-2008.  62:356-362. 2013
  • Predictive accuracy of the veterans aging cohort study index for mortality with HIV infection: A north american cross cohort analysis.  62:149-163. 2013
  • Multimorbidity patterns in HIV-infected patients: The role of obesity in chronic disease clustering.  61:600-605. 2012
  • Prevalence of proteinuria and elevated serum cystatin c among hiv-infected adolescents in the reaching for Excellence in Adolescent Care and Health (REACH) study.  61:499-506. 2012
  • Serum (1→3)-β-D-glucan levels in HIV-infected individuals are associated with immunosuppression, inflammation, and cardiopulmonary function.  61:462-468. 2012
  • Pain, mood, and substance abuse in HIV: Implications for clinic visit utilization, antiretroviral therapy adherence, and virologic failure.  61:164-170. 2012
  • Six-month hemoglobin concentration and its association with subsequent mortality among adults on antiretroviral therapy in Lusaka, Zambia.  61:120-123. 2012
  • HIV and aging: State of knowledge and areas of critical need for research. a report to the NIH office of AIDS research by the HIV and aging working group.  60. 2012
  • Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials.  60:33-42. 2012
  • Childhood trauma and health outcomes in HIV-infected patients: An exploration of causal pathways.  59:409-416. 2012
  • Early retention in HIV care and viral load suppression: Implications for a test and treat approach to HIV prevention.  59:86-93. 2012
  • Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia.  58:475-481. 2011
  • Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.  58:253-260. 2011
  • Interleukin-2 production by polyfunctional HIV-1-specific CD8 T cells is associated with enhanced viral suppression.  58:132-140. 2011
  • Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe.  57:157-164. 2011
  • Prevention of mother-to-child transmission of HIV in Thailand: Physicians' attitudes on zidovudine use, pregnancy termination, and willingness to provide care.  21:217-222. 1999
  • Declining CD4+ T-lymphocyte counts are associated with increased risk of enteric parasitosis and chronic diarrhea: Results of a 3-year longitudinal study.  20:154-159. 1999
  • Th1/Th2 cytokine expression in saliva of HIV-positive and HIV-negative individuals: A pilot study in HIV-positive individuals with oropharyngeal candidiasis.  19:373-380. 1998
  • Erratum: Serum retinol and HIV-1 RNA viral load in rapid and slow progressors (Journal of Acquired Immune Deficiency and Human Retrovirology (1998) 18 (21-26)).  18:401-406. 1998
  • Serum retinol and HIV-1 RNA viral load in rapid and slow progressors..  18:401-406. 1998
  • Serum retinol and HIV-1 RNA viral load in rapid and slow progressors.  18:21-26. 1998
  • Polyamine pools in HIV-infected cells.  17:101-103. 1998
  • Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-α2ain patients with HIV.  16:247-253. 1997
  • Rapid and selective depletion of CD4 + T lymphocytes and preferential loss of memory cells on interaction of mononuclear cells with HIV-1 glycoprotein-expressing cells.  16:74-82. 1997
  • Complement activation by HIV-1-infected cells: The role of transmembrane glycoprotein gp41.  14:102-109. 1997
  • Assessment of antiretroviral therapy by plasma viral load testing: Standard and ICD HIV-1 p24 antigen and viral RNA (QC-PCR) assays compared.  10:139-149. 1995
  • Zidovudine for the prevention of vertical HIV transmission: A decision analytic approach.  9:401-407. 1995
  • Issues in combination antiretroviral therapy: A review.  7:S24-S37. 1994
  • Pathogenicity and diversity of hiv and implications for clinical management: A review.  7:S2-S11. 1994
  • International Standard Serial Number (issn)

  • 1077-9450
  • 1525-4135
  • Electronic International Standard Serial Number (eissn)

  • 1077-9450